Systemic Lymphadenectomy Cannot Be Recommended for Low-Risk Corpus Cancer

被引:14
作者
Hidaka, Takao [1 ]
Nakashima, Akitoshi [1 ]
Shima, Tomoko [1 ]
Hasegawa, Toru [1 ]
Saito, Shigeru [1 ]
机构
[1] Toyama Univ, Fac Med, Dept Obstet & Gynecol, Toyama 9300194, Japan
关键词
D O I
10.1155/2010/490219
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective. The objective of this study is to ascertain whether omission of lymphadenectomy could be possible when uterine corpus cancer is considered low-risk based on intraoperative pathologic indicators. Patient and Methods. Between 1998 and 2007, a total of 83 patients with low risk corpus cancer (endometrioid type, grade 1 or 2, myometrial invasion <= 50%, and no intraoperative evidence of macroscopic extrauterine spread, including pelvic and paraaortic lymph node swelling and adnexal metastasis) underwent the total abdominal hysterectomy and bilateral salpingo-oophorectomy without lymphadenectomy. A retrospective review of the medical records was performed, and the disease-free survival (DFS), overall survival (OS), peri-and postoperative morbidities and complications were evaluated. Results. The 5-year DFS rates and the 5-year OS rates were 97.6% and 98.8%, respectively. No patient presented postoperative leg lymphedema and deep venous thrombosis. Conclusion. Omission of lymphadenectomy did not worsen the DFS or OS. The present findings suggest that systemic lymphadenectomy could be omitted in low-risk endometrial carcinoma.
引用
收藏
页数:5
相关论文
共 32 条
[1]  
[Anonymous], 1989, GYNECOL ONCOL, V35, P125, DOI DOI 10.1016/0090-8258(89)90027-9
[2]   Surgical staging for patients presenting with grade 1 endometrial carcinoma [J].
Ben-Shachar, I ;
Pavelka, J ;
Cohn, DE ;
Copeland, LJ ;
Ramirez, N ;
Manolitsas, T ;
Fowler, JM .
OBSTETRICS AND GYNECOLOGY, 2005, 105 (03) :487-493
[3]  
BORONOW RC, 1984, OBSTET GYNECOL, V63, P825
[4]   REPRODUCTIVE, MENSTRUAL, AND MEDICAL RISK-FACTORS FOR ENDOMETRIAL CANCER - RESULTS FROM A CASE-CONTROL STUDY [J].
BRINTON, LA ;
BERMAN, ML ;
MORTEL, R ;
TWIGGS, LB ;
BARRETT, RJ ;
WILBANKS, GD ;
LANNOM, L ;
HOOVER, RN .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (05) :1317-1325
[5]   GOOD OUTCOME ASSOCIATED WITH A STANDARDIZED TREATMENT PROTOCOL USING SELECTIVE POSTOPERATIVE RADIATION IN PATIENTS WITH CLINICAL STAGE-I ADENOCARCINOMA OF THE ENDOMETRIUM [J].
CAREY, MS ;
OCONNELL, GJ ;
JOHANSON, CR ;
GOODYEAR, MD ;
MURPHY, KJ ;
DAYA, DM ;
SCHEPANSKY, A ;
PELOQUIN, A ;
LUMSDEN, BJ .
GYNECOLOGIC ONCOLOGY, 1995, 57 (02) :138-144
[6]   The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology [J].
Chi, D. S. ;
Barakat, R. R. ;
Palayekar, M. J. ;
Levine, D. A. ;
Sonoda, Y. ;
Alektiar, K. ;
Brown, C. L. ;
Abu-Rustum, N. R. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (02) :269-273
[7]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[8]  
2-8
[9]   Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study [J].
Dimopoulos, MA ;
Papadimitriou, CA ;
Georgoulias, V ;
Moulopoulos, LA ;
Aravantinos, G ;
Gika, D ;
Karpathios, S ;
Stamatelopoulos, S .
GYNECOLOGIC ONCOLOGY, 2000, 78 (01) :52-57
[10]   Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study [J].
Fleming, GF ;
Brurietto, VL ;
Cella, D ;
Look, KY ;
Reid, GCH ;
Munkarah, AR ;
Kline, R ;
Burger, RA ;
Goodman, A ;
Burks, RT .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2159-2166